Catalyst Wire Dossier Catalyst Wire Dossier

Galcanezumab

galcanezumab · Eli Lilly and Company
Drug timelines are a Plus or Pro feature.

22 regulatory and trial events tracked for Galcanezumab, covering 2018-11-23 to 2026-02-27. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine [Phase 3]

See pricing